AB0438 TAPERING BIOLOGICAL DMARD IN RHEUMATOID ARTHRITIS: REAL-WORLD EVIDENCE

• Published in: Annals of the rheumatic diseases Vol. 82; no. Suppl 1; pp. 1407 - 1408
• Main Authors: Rojas Zuleta, W G, Barbosa, M, Becerra-Arias, C, Felipe Díaz, O J, Donado Gómez, J H, González, L A, N Duque Zapata
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2023
• Subjects: Ankylosing spondylitis; Biological products; Drug dosages; Etanercept; Infliximab; Intravenous administration; Monoclonal antibodies; Optimization; Patients; Psoriatic arthritis; Public health; Quality of life; Remission; Rheumatoid arthritis; Rheumatology; Rituximab; Statistical analysis; Tumor necrosis factor-α

Backgroundbiological DMARDs have revolutionized the treatment of rheumatoid arthritis (RA), demonstrating effectiveness in terms of symptom control, improvement in quality of life and radiographic progression. However, their high-cost impacts global health systems. Therefore, tapering strategies are...